$ cat ./records/gates-foundation-commits-up-to-125-million-to-end-acute-covid-19--2022.txt
Gates Foundation Commits Up to $125 Million to End Acute COVID-19 Phase and Strengthen Global Disease Monitoring
[RECORD.TXT] · cat --full
In May 2022, Bill Gates announced up to $125 million across four areas: strengthening health systems in low-income countries; enhancing integrated global disease monitoring; expanding LMIC access to mRNA vaccines; and building vaccine manufacturing capacity in developing countries. The commitment built on more than $2 billion in prior COVID-19 contributions and specifically targeted integrated disease surveillance infrastructure to help all countries detect and monitor emerging infectious diseases before they become pandemics.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates-Backed CEPI Launches $50 Million Funding Call for Rift Valley Fever Vaccine Phase Trials in Africa
Next →
Gates Foundation Pledges $154 Million to CEPI 100 Days Mission for Pandemic Vaccines in Under 100 Days
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.